0001209191-20-041566.txt : 20200707
0001209191-20-041566.hdr.sgml : 20200707
20200707192552
ACCESSION NUMBER: 0001209191-20-041566
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200702
FILED AS OF DATE: 20200707
DATE AS OF CHANGE: 20200707
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stein Steven H
CENTRAL INDEX KEY: 0001673776
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 201016997
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-02
0
0000879169
INCYTE CORP
INCY
0001673776
Stein Steven H
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19803
0
1
0
0
EVP & Chief Medical Officer
Common Stock
2020-07-02
4
A
0
6661
0.00
A
105015
D
Common Stock
2020-07-02
4
F
0
1474
106.47
D
103541
D
Common Stock
2020-07-06
4
F
0
269
107.79
D
103272
D
Common Stock
2020-07-06
4
S
0
2522
106.40
D
100750
D
Common Stock
2020-07-06
4
M
0
596
83.83
A
101346
D
Common Stock
2020-07-06
4
S
0
596
107.31
D
100750
D
Common Stock
2020-07-06
4
M
0
12132
83.83
A
112882
D
Common Stock
2020-07-06
4
S
0
12132
107.31
D
100750
D
Common Stock
2020-07-06
4
M
0
10437
72.27
A
111187
D
Common Stock
2020-07-06
4
S
0
10437
107.31
D
100750
D
Common Stock
2020-07-06
4
M
0
10437
68.62
A
111187
D
Common Stock
2020-07-06
4
S
0
10437
107.31
D
100750
D
Employee Stock Option (right to buy)
106.47
2020-07-02
4
A
0
12743
0.00
A
2030-07-01
Common Stock
12743
12743
D
Incentive Stock Option (right to buy)
83.83
2020-07-06
4
M
0
596
0.00
D
2026-07-14
Common Stock
596
0
D
Non-Qualified Stock Option (right to buy)
83.83
2020-07-06
4
M
0
12132
0.00
D
2026-07-14
Common Stock
12132
1194
D
Non-Qualified Stock Option (right to buy)
72.27
2020-07-06
4
M
0
10437
0.00
D
2029-01-03
Common Stock
10437
12335
D
Non-Qualified Stock Option (right to buy)
68.62
2020-07-06
4
M
0
10437
0.00
D
2028-07-01
Common Stock
10437
12334
D
Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Steven Stein's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.
Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.
Represents weighted average sale price. Actual sale prices ranged from $105.52 - $107.29.
Represents weighted average sale price. Actual sale prices ranged from $105.64 - $108.24.
Represents weighted average sale price. Actual sale prices ranged from $105.65 - $108.48
Including the July 2, 2020 Restricted Stock Unit Grant, this includes an aggregate of 96,857 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.
Beginning July 2, 2020, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years.
Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
/s/ Michael J. Purvis, Attorney-In-Fact
2020-07-07